ABVC
ABVC BioPharma, Inc. Common Stock
stockNASDAQ
american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.99 | 2026-11-03 | -0.55% | 0.994 |
| 1M | 1.00 | 2026-10-09 | -2.03% | 0.923 |
| 3M | 0.95 | 2026-08-10 | +3.11% | 1.449 |
| 6M | 1.02 | 2026-05-11 | -3.95% | 1.216 |
| 1Y | 2.85 | 2025-11-10 | -65.63% | 1.551 |
| 2Y | 0.53 | 2024-11-11 | +86.22% | — |
| 5Y | 32.90 | 2021-11-10 | -97.02% | 0.726 |
ABVC BioPharma, Inc. Common Stock (NASDAQ:ABVC) stock price today is $0.98, and today's volume is 25,466. ABVC is down 3.953% today. The 30 day average volume is 55,967. ABVC market cap is $26.15M with 26.69M shares outstanding.